IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the leading provider of radiopharmaceutical production solutions, launches Cyclone iKure, a dedicated cyclotron for routine Astatine-211 (At-211) production. Designed for alpha-beam irradiation, this new cyclotron enables radiopharmaceutical manufacturers, research institutions and healthcare providers to accelerate access to targeted alpha therapies with the reliability and quality required for clinical-scale programs.

Targeted alpha therapy is emerging as an important area of development in precision oncology. Alpha-emitting isotopes deliver highly concentrated radiation over a very short distance, destroying cancer cells with remarkable precision, with limited exposure to surrounding healthy tissue. Among alpha emitters, At-211 is attracting attention for its chemical properties and half-life. Yet translating clinical promises into routine patient care has been held back by a fundamental challenge: establishing reliable production infrastructure at scale. With Cyclone iKure, IBA aims to address this production challenge.

Cyclone iKure has been designed specifically for At-211-isotope workflows. It has been engineered to deliver consistent, high-yield At-211 output at production scale. Automated processes simplify daily operations and minimise operator radiation exposure, while a compact footprint allows the system to fit within limited infrastructure, reducing site preparation complexity and cost. The system is designed to meet applicable CE marking requirements and regulatory compliance.

Cyclone iKure draws on IBA’s four decades of cyclotron engineering expertise, the same foundation behind the Cyclone KIUBE, Cyclone IKON and Cyclone KEY platforms that serve radiopharmaceutical producers and hospitals worldwide. With this launch, IBA extends its cyclotron portfolio from diagnostic PET & SPECT imaging to therapeutic alpha-isotope production.

“Targeted alpha therapy has significant clinical potential, but realising it at scale depends on reliable and scalable production infrastructure,” said Charles Kumps, President of IBA RadioPharma Solutions. “With Cyclone iKure, we are bringing to the alpha-therapy space the precision and dependability that IBA is known for. Designed for routine At-211 production, it is built to help radiopharma innovators and clinicians move from early-stage programs to routine clinical application and to make targeted alpha therapies accessible to the patients who need them.”